HK1252741A1 - 用於治療神經疾病的組合物和方法 - Google Patents
用於治療神經疾病的組合物和方法Info
- Publication number
- HK1252741A1 HK1252741A1 HK18112060.0A HK18112060A HK1252741A1 HK 1252741 A1 HK1252741 A1 HK 1252741A1 HK 18112060 A HK18112060 A HK 18112060A HK 1252741 A1 HK1252741 A1 HK 1252741A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- neurological disorders
- treating neurological
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220077P | 2015-09-17 | 2015-09-17 | |
US201562220087P | 2015-09-17 | 2015-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1252741A1 true HK1252741A1 (zh) | 2019-05-31 |
Family
ID=58289686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18112060.0A HK1252741A1 (zh) | 2015-09-17 | 2018-09-19 | 用於治療神經疾病的組合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180193414A1 (zh) |
EP (1) | EP3349760A4 (zh) |
JP (1) | JP2018531926A (zh) |
KR (1) | KR20200108514A (zh) |
CN (1) | CN108348528A (zh) |
AU (1) | AU2016324317A1 (zh) |
CA (1) | CA2998491A1 (zh) |
HK (1) | HK1252741A1 (zh) |
WO (1) | WO2017049252A1 (zh) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7097070B2 (ja) * | 2015-10-01 | 2022-07-07 | ゴレイニ インコーポレイテッド | クロライドチャネルの標的発現及びその使用方法 |
WO2017153995A1 (en) | 2016-03-09 | 2017-09-14 | Assaf Fadi | Using dreadd for neuronal modulation in treating neuronal diseases |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
AU2017321708B2 (en) * | 2016-08-31 | 2024-01-04 | Rutgers, The State University Of New Jersey | Methods and compositions for treating diseases and disorders of the nervous system |
US11713470B2 (en) | 2017-03-20 | 2023-08-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted gene therapies for pain and other neuro-related disorders |
KR102606810B1 (ko) * | 2017-05-05 | 2023-11-27 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 오토펄린을 발현시키기 위한 조성물 및 방법 |
WO2019090001A1 (en) | 2017-11-02 | 2019-05-09 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
US11376337B2 (en) | 2017-11-02 | 2022-07-05 | California Institute Of Technology | Expression of neuropeptides |
WO2019094778A1 (en) * | 2017-11-10 | 2019-05-16 | Scott Sternson | Modified ligand-gated ion channels and methods of use |
US10538571B2 (en) | 2017-11-27 | 2020-01-21 | Coda Biotherapeutics, Inc. | Compositions and methods for neurological diseases |
WO2019113538A2 (en) * | 2017-12-07 | 2019-06-13 | California Institute Of Technology | Methods and systems for noninvasive control of brain cells and related vectors and compositions |
EP3710010A4 (en) * | 2017-12-20 | 2021-09-22 | Ovid Therapeutics Inc. | USE OF HM4DI IN TREATMENT OF SEQUENCE DISEASES |
EP3749325A1 (en) | 2018-02-07 | 2020-12-16 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Dreadd actuators |
WO2019173258A1 (en) * | 2018-03-05 | 2019-09-12 | Academia Sinica | Methods and kits for diagnosing and/or treating peripheral neuropathy |
CA3091752A1 (en) | 2018-03-08 | 2019-09-12 | Victoria Link Ltd | Treatment of demyelinating diseases |
EP3812373A4 (en) * | 2018-06-21 | 2021-06-16 | National Institutes For Quantum And Radiological Science And Technology | NEW COMPOUND BONDING TO A CUSTOM-MADE RECEIVER, IMAGING PROCESS FOR CUSTOM-MADE RECEIVER, AGONIST OR ANTAGONIST, THERAPEUTIC AGENT, ACCOMPANYING DIAGNOSIS AGENT, AND NERVOUS CELL IMAGING PROCESS |
EP3829718A4 (en) * | 2018-07-31 | 2022-06-22 | Cornell University | GENE THERAPY METHODS FOR CONTROLLING ORGAN FUNCTION |
CN109266682B (zh) * | 2018-09-29 | 2022-04-01 | 中国科学院武汉物理与数学研究所 | 一种神经细胞快速逆行跨突触标记的方法及应用 |
CN111172192B (zh) * | 2018-11-13 | 2024-04-23 | 四川横竖生物科技股份有限公司 | 基于hNPY的基因过表达嵌合动物模型构建方法及其应用 |
WO2020176796A1 (en) * | 2019-02-27 | 2020-09-03 | Lau Warren C | Gene therapy for addiction disorders |
JPWO2021002352A1 (zh) * | 2019-07-01 | 2021-01-07 | ||
CN110592132A (zh) * | 2019-10-09 | 2019-12-20 | 武汉博欧特生物科技有限公司 | 恶臭假单胞菌kt2440蛋白同源表达载体的构建及表达、纯化方法 |
MX2022006895A (es) * | 2019-12-05 | 2022-11-09 | Univ Columbia | Estabilizacion de retromero para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. |
GB201918879D0 (en) * | 2019-12-19 | 2020-02-05 | Ucl Business Ltd | Treatment of chronic pain |
JP2023509981A (ja) * | 2020-01-10 | 2023-03-10 | エキリーブル バイオファーマシューティカルズ べスローテン フェンノートシャップ | アベルメクチンによる神経障害の治療 |
GB202004498D0 (en) * | 2020-03-27 | 2020-05-13 | Ucl Business Ltd | Activity-dependent gene therapy for neurological disorders |
TW202204343A (zh) * | 2020-03-30 | 2022-02-01 | 德商百靈佳殷格翰國際股份有限公司 | 經取代之3-苯氧基氮雜環丁烷-1-基-吡 |
JP2023522883A (ja) * | 2020-04-15 | 2023-06-01 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 神経学的障害を処置するための組成物および方法 |
CN113667697A (zh) * | 2020-05-14 | 2021-11-19 | 上海家化联合股份有限公司 | 基于人trpv1受体过表达细胞株的评价方法 |
CN111658677B (zh) * | 2020-06-08 | 2021-11-30 | 连庆泉 | 化学遗传学药物组合物在制备防治丙泊酚成瘾药物中的应用 |
KR20230031207A (ko) * | 2020-06-30 | 2023-03-07 | 도레이 카부시키가이샤 | 대사이상을 수반하는 질환 또는 증후군에 있어서의 근력 저하 증상의 개선제 또는 예방제 |
WO2022017630A1 (en) * | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
CN111793649A (zh) * | 2020-07-29 | 2020-10-20 | 大理大学 | 含有mc1r基因的重组腺相关病毒的应用 |
JP2024505197A (ja) * | 2021-01-25 | 2024-02-05 | トレイムス バイオ, インコーポレイテッド | 焦点てんかんおよび神経因性疼痛を処置するためのアデノ随伴ウイルスカプシドおよび操作されたリガンド依存性イオンチャネル |
US11760788B2 (en) * | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
WO2023278295A1 (en) | 2021-06-29 | 2023-01-05 | The Broad Institute, Inc. | Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability |
US20230039652A1 (en) * | 2021-07-09 | 2023-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
CN113866415B (zh) * | 2021-10-13 | 2024-02-06 | 戴勇 | 乳腺癌脑转移的诊断及预后标志物 |
WO2023114892A2 (en) * | 2021-12-15 | 2023-06-22 | The Trustees Of Columbia University In The City Of New York | Regulation of immune responses through selective neural activation |
WO2023108485A1 (zh) * | 2021-12-15 | 2023-06-22 | 中国科学院深圳先进技术研究院 | 通过蓝斑核及其周边区域调控血管内皮细胞异质性的方法 |
WO2023180957A1 (en) * | 2022-03-22 | 2023-09-28 | Equilibre Biopharmaceuticals Bv | Methods of using avermectin compositions for the treatment of pain and dosing regimens |
US20240002463A1 (en) * | 2022-04-27 | 2024-01-04 | Howard Hughes Medical Institute | Chemogenetic receptors and methods of making and using |
WO2024073483A2 (en) * | 2022-09-28 | 2024-04-04 | The General Hospital Corporation | 4-1bbl and il-12 therapy for treatment of glioblastoma |
CN116115739B (zh) * | 2022-12-29 | 2024-01-09 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 胃动素及其受体激动剂的应用 |
CN116789765B (zh) * | 2023-06-30 | 2024-06-18 | 湖南中晟全肽生物科技股份有限公司 | 一种激活oprm1基因编码的受体的多肽及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
JP4580106B2 (ja) * | 1999-03-02 | 2010-11-10 | ライフ テクノロジーズ コーポレーション | 核酸の組換えクローニングにおける使用のための組成物および方法 |
CA2438386A1 (en) * | 2001-02-16 | 2002-08-29 | Bristol-Myers Squibb Company | Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof |
US20070065904A1 (en) * | 2002-03-20 | 2007-03-22 | Matthew Gonda | Recombinant expression vectors for functional nav1.9 sodium channels |
WO2008061209A2 (en) * | 2006-11-15 | 2008-05-22 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20080289058A1 (en) * | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
EP2093281A1 (en) * | 2008-02-19 | 2009-08-26 | Kapsid Link, S.L. | Protein nanocarriers, process for obtaining them and applications |
US8435762B2 (en) * | 2008-10-09 | 2013-05-07 | Howard Hughes Medical Institute | Chimeric ligand-gated ion channels and methods of use thereof |
US20120207840A1 (en) * | 2011-02-10 | 2012-08-16 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer |
WO2013126521A1 (en) * | 2012-02-21 | 2013-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating neurogenic disorders of the pelvic floor |
US9624288B2 (en) * | 2012-12-10 | 2017-04-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Engineered receptors and their use |
GB201404470D0 (en) * | 2014-03-13 | 2014-04-30 | Ucl Business Plc | Therapeutic methods and materials |
-
2016
- 2016-09-17 WO PCT/US2016/052384 patent/WO2017049252A1/en unknown
- 2016-09-17 JP JP2018515123A patent/JP2018531926A/ja active Pending
- 2016-09-17 EP EP16847512.7A patent/EP3349760A4/en not_active Withdrawn
- 2016-09-17 KR KR1020187008264A patent/KR20200108514A/ko unknown
- 2016-09-17 CN CN201680054327.4A patent/CN108348528A/zh active Pending
- 2016-09-17 CA CA2998491A patent/CA2998491A1/en not_active Abandoned
- 2016-09-17 AU AU2016324317A patent/AU2016324317A1/en not_active Abandoned
-
2018
- 2018-02-12 US US15/894,633 patent/US20180193414A1/en not_active Abandoned
- 2018-09-19 HK HK18112060.0A patent/HK1252741A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017049252A1 (en) | 2017-03-23 |
JP2018531926A (ja) | 2018-11-01 |
US20180193414A1 (en) | 2018-07-12 |
KR20200108514A (ko) | 2020-09-21 |
CA2998491A1 (en) | 2017-03-23 |
AU2016324317A1 (en) | 2018-03-08 |
CN108348528A (zh) | 2018-07-31 |
EP3349760A4 (en) | 2019-03-27 |
EP3349760A1 (en) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252741A1 (zh) | 用於治療神經疾病的組合物和方法 | |
ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
IL251721A0 (en) | Preparations and methods for the treatment of diseases of the central nervous system | |
RS60642B1 (sr) | Kompozicije i postupci za lečenje poremećaja cns-a | |
RS61530B1 (sr) | Kompozicije i postupci za lečenje poremećaja cns | |
HUE049014T2 (hu) | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére | |
IL257252A (en) | Methods for treating fgf21-related disorders | |
IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
GB2558326B (en) | Methods and compositions for inhibiting and treating neurological conditions | |
IL250715A0 (en) | Preparations and methods for the treatment of cultural disorders | |
EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
PT3119911T (pt) | Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+ | |
IL270114B1 (en) | Methods and compounds for the treatment of neurological diseases | |
HK1256298A1 (zh) | 用於治療和預防神經退化性病症的組合物和方法 | |
EP3262065C0 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES | |
SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders |